Cylex, Inc is a biotechnology company developing and manufacturing products that use the immune system for predicting and managing human health. It is the first company to offer a patent- protected, FDA-approved cellular assay of immune system function, trademarked as ImmuKnow, that measures the vitality of a patient's immune system from a single drop of blood. This test may assist physicians in managing the treatment of diseases such as HIV, HCV, cancer and autoimmune disorders, as well as bone marrow and solid organ transplantation.
In September 2006, Cylex announced study results on the effectiveness of ImmuKnow in minimizing the risk of infection and rejection in post-transplant patients. Testing with ImmuKnow enabled doctors to tailor immunosuppressant drug regimens to prevent organ rejection while avoiding infection. Such information could help physicians reduce the use of immunosuppressive drugs, which have multiple serious side effects associated with their use, and lower the number of liver biopsies needed to monitor the transplant.